PRF Technologies (PRFX) Research & Development (2020 - 2024)
PRF Technologies (PRFX) posted Research & Development of -$6.7 million for Q2 2024, down 40.55% on a QoQ basis from -$4.7 million in Q1 2024, and down 634.91% year-over-year from $1.2 million in Q3 2023.
PRF Technologies (PRFX) Research & Development (2020 - 2024) Analysis & Trends
PRF Technologies' Research & Development history runs 5 years deep, the most recent figure standing at -$6.7 million for Q2 2024.
- Quarterly Research & Development fell 634.91% year-over-year to -$6.7 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was -$8.1 million (down 241.64% YoY) and the FY2025 annual result came in at $163000.0, down 98.61% from the prior year.
- Research & Development was -$6.7 million for Q2 2024 at PRF Technologies, down from -$4.7 million in the prior quarter.
- Across five years, Research & Development topped out at $6.9 million in Q4 2022 and bottomed at -$6.7 million in Q2 2024.
- A 5-year average of $125777.8 and a median of $564500.0 in 2021 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 3001.12% in 2021, while the deepest fall reached 4187.5% in 2021.
- PRF Technologies' Research & Development stood at $446000.0 in 2020, then grew by 24.66% to $556000.0 in 2021, then jumped by 1140.11% to $6.9 million in 2022, then slumped by 60.17% to $2.7 million in 2023, then tumbled by 342.72% to -$6.7 million in 2024.
- Business Quant data shows PRFX's Research & Development at -$6.7 million in Q2 2024, -$4.7 million in Q1 2024, and $2.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | PRF Technologies | 714,066.24 | -326,933.76 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -6.67 Mn |
| Mar 31, 2024 | -4.74 Mn |
| Dec 31, 2023 | 2.75 Mn |
| Sep 30, 2023 | 589,000.00 |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | 1.45 Mn |
| Dec 31, 2022 | 6.90 Mn |
| Sep 30, 2022 | -3.90 Mn |
| Jun 30, 2022 | 743,000.00 |
| Mar 31, 2022 | 680,000.00 |
| Dec 31, 2021 | 556,000.00 |
| Sep 30, 2021 | 573,000.00 |
| Jun 30, 2021 | 2.76 Mn |
| Mar 31, 2021 | -1.03 Mn |
| Dec 31, 2020 | 446,000.00 |
| Sep 30, 2020 | -157,000.00 |
| Jun 30, 2020 | 89,000.00 |
| Mar 31, 2020 | -24,000.00 |